TY - JOUR
T1 - A combined strategy to improve the development of a coral antivenom against micrurus spp.
AU - de Castro, Karen Larissa Pereira
AU - Lopes-De-souza, Letícia
AU - de Oliveira, Daysiane
AU - Machado-De-ávila, Ricardo Andrez
AU - Paiva, Ana Luiza Bittencourt
AU - de Freitas, Cláudio F.
AU - Ho, Paulo Lee
AU - Chávez-Olórtegui, Carlos
AU - Guerra-Duarte, Clara
N1 - Publisher Copyright:
© 2019 de Castro, Lopes-de-Souza, de Oliveira, Machado-de-Ávila, Paiva, de Freitas, Ho, Chávez-Olórtegui and Guerra-Duarte.
PY - 2019
Y1 - 2019
N2 - Accidents involving Micrurus snakes are not the most common ones but are noteworthy due to their severity. Victims envenomed by Micrurus snakes are at high risk of death and therefore must be treated with coral antivenom. In Brazil, the immunization mixture used to fabricate coral antivenom contains Micrurus frontalis and Micrurus corallinus venoms, which are difficult to be obtained in adequate amounts. Different approaches to solve the venom limitation problem have been attempted, including the use of synthetic and recombinant antigens as substitutes. The present work proposes a combined immunization protocol, using priming doses of M. frontalis venom and booster doses of synthetic B-cell epitopes derived from M. corallinus toxins (four three-finger toxins-3FTX; and one phospholipase A2-PLA2 ) to obtain coral antivenom in a rabbit model. Immunized animals elicited a humoral response against both M. frontalis and M. corallinus venoms, as detected by sera reactivity in ELISA and Western Blot. Relevant cross-reactivity of the obtained sera with other Micrurus species (Micrurus altirostris, Micrurus lemniscatus, Micrurus spixii, Micrurus surinamensis) venoms was also observed. The elicited antibodies were able to neutralize PLA2 activity of both M. frontalis and M. corallinus venoms. In vivo, immunized rabbit sera completely protected mice from a challenge with 1.5 median lethal dose (LD50 ) of M. corallinus venom and 50% of mice challenged with 1.5 LD50 of M. frontalis venom. These results show that this combined protocol may be a suitable alternative to reduce the amount of venom used in coral antivenom production in Brazil.
AB - Accidents involving Micrurus snakes are not the most common ones but are noteworthy due to their severity. Victims envenomed by Micrurus snakes are at high risk of death and therefore must be treated with coral antivenom. In Brazil, the immunization mixture used to fabricate coral antivenom contains Micrurus frontalis and Micrurus corallinus venoms, which are difficult to be obtained in adequate amounts. Different approaches to solve the venom limitation problem have been attempted, including the use of synthetic and recombinant antigens as substitutes. The present work proposes a combined immunization protocol, using priming doses of M. frontalis venom and booster doses of synthetic B-cell epitopes derived from M. corallinus toxins (four three-finger toxins-3FTX; and one phospholipase A2-PLA2 ) to obtain coral antivenom in a rabbit model. Immunized animals elicited a humoral response against both M. frontalis and M. corallinus venoms, as detected by sera reactivity in ELISA and Western Blot. Relevant cross-reactivity of the obtained sera with other Micrurus species (Micrurus altirostris, Micrurus lemniscatus, Micrurus spixii, Micrurus surinamensis) venoms was also observed. The elicited antibodies were able to neutralize PLA2 activity of both M. frontalis and M. corallinus venoms. In vivo, immunized rabbit sera completely protected mice from a challenge with 1.5 median lethal dose (LD50 ) of M. corallinus venom and 50% of mice challenged with 1.5 LD50 of M. frontalis venom. These results show that this combined protocol may be a suitable alternative to reduce the amount of venom used in coral antivenom production in Brazil.
KW - Antivenom
KW - Epitopes
KW - Micrurus
KW - Phospholipase A
KW - Snake
KW - Synthetic peptides
KW - Three-finger toxins
UR - http://www.scopus.com/inward/record.url?scp=85074559141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074559141&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2019.02422
DO - 10.3389/fimmu.2019.02422
M3 - Article
C2 - 31695693
AN - SCOPUS:85074559141
SN - 1664-3224
VL - 10
JO - Frontiers in immunology
JF - Frontiers in immunology
IS - OCT
M1 - 2422
ER -